Personalized dendritic cell-based tumor immunotherapy

Nona Janikashvili, Nicolas Laemonier, Emmanuel Katsanis

Research output: Contribution to journalReview article

38 Scopus citations

Abstract

Advances in the understanding of the immunoregulatory functions of dendritic cells (DCs) in animal models and humans have led to their exploitation as anticancer vaccines. Although DC-based immunotherapy has proven clinically safe and efficient to induce tumor-specific immune responses, only a limited number of objective clinical responses have been reported in cancer patients. These relatively disappointing results have prompted the evaluation of multiple approaches to improve the efficacy of DC vaccines. The topic of this review focuses on personalized DC-based anticancer vaccines, which in theory have the potential to present to the host immune system the entire repertoire of antigens harbored by autologous tumor cells. We also discuss the implementation of these vaccines in cancer therapeutic strategies, their limitations and the future challenges for effective immunotherapy against cancer.

Original languageEnglish (US)
Pages (from-to)57-68
Number of pages12
JournalImmunotherapy
Volume2
Issue number1
DOIs
StatePublished - Jan 2010

Keywords

  • Anticancer immune response
  • Chaperone protein
  • Dendritic cell idiotype
  • Personalized tumor vaccine
  • Tumor lysate

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Fingerprint Dive into the research topics of 'Personalized dendritic cell-based tumor immunotherapy'. Together they form a unique fingerprint.

  • Cite this